Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder^*

References

• Kessler RC, Berglund P, Demler O, . The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289:3095–105
   PubMed Web of Science ®Google Scholar
• World Health Organization. The World Health Report. Mental Health: New Understanding. New HopeGeneva, Switzerland: World Health Organization, 2001
   Google Scholar
• Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007; 151:737–48
   PubMed Web of Science ®Google Scholar
• Krishnan KR. Revisiting monoamine oxidase inhibitors. J Clin Psychiatry 2007; 68 (Suppl 8) 35–41
   PubMed Web of Science ®Google Scholar
• Schatzberg AF. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. J Clin Psychiatry 2007; 68 (Suppl 8) 26–34
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Drug details for venlafaxineWashington, DC. 2007. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [Last accessed 15 October 2007]
   Google Scholar
• Food and Drug Administration. Drug details for duloxetineWashington, DC. 2007. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [Last accessed 15 October 2007]
   Google Scholar
• Deecher DC, Beyer CE, Johnston G, . Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006; 318:657–65
   PubMed Web of Science ®Google Scholar
• Johnston G, Bray J, Andree T, . Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. Poster presented at: Society for Neuroscience Annual MeetingWashington, DCNovember 3–5, 2005
   Google Scholar
• Pristiq [package insert]Philadelphia, PA: Wyeth Pharmaceuticals, 2008
   Google Scholar
• Liebowitz M, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 2007; 68:1663–72
   PubMed Web of Science ®Google Scholar
• DeMartinis NA, Yeung PP, Entsuah R, . A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007; 68:677–88
   PubMed Web of Science ®Google Scholar
• Septien-Velez L, Pitrosky B, Padmanabhan SK, . A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 2007; 22:338–47
   PubMed Web of Science ®Google Scholar
• Thase ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group. J Clin Psychiatry 1997; 58:393–8
   PubMed Web of Science ®Google Scholar
• Cunningham LA. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann Clin Psychiatry 1997; 9:157–64
   PubMedGoogle Scholar
• Hudson JI, Wohlreich MM, Kajdasz DK, . Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol 2005; 20:327–41
   PubMed Web of Science ®Google Scholar
• Fava M, Mulroy R, Alpert J, . Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry 1997; 154:1760–2
   PubMed Web of Science ®Google Scholar
• Perahia DG, Kajdasz DK, Desaiah D, . Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord 2005; 89:207–12
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56–62
   PubMed Web of Science ®Google Scholar
• Guy W. Clinical Global Impressions. Publication ADM 76–338. ECDEU Assessment Manual for PsychopharmacologyRockville, MD: US Department of Health, Education, and Welfare, 1976;217–22
   Google Scholar
• Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382–9
   PubMed Web of Science ®Google Scholar
• DeLoach LJ, Higgins MS, Caplan AB, . The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 1998; 86:102–6
   PubMed Web of Science ®Google Scholar
• Bech P, Gram LF, Dein E, . Quantitative rating of depressive states. Acta Psychiatr Scand 1975; 51:161–70
   PubMed Web of Science ®Google Scholar
• Lipman RS. Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacol Bull 1982; 18:69–77
   PubMedGoogle Scholar
• Sheehan DV. Sheehan Disability Scale. Handbook of Psychiatric MeasuresRush AJ, Pincus HA, First MB, . Washington, DC: American Psychiatric Association, 2000;113–5
   Google Scholar
• World Health Organization. Wellbeing measures in primary health care/the DepCare ProjectCopenhagen, Denmark: WHO Regional Office for Europe, 1998
   Google Scholar
• Fava M, Mallinckrodt CH, Detke MJ, . The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 2004; 65:521–30
   PubMed Web of Science ®Google Scholar
• Liebowitz M, Montgomery S, Boyer P, . Evaluation of the efficacy and safety of fixed doses of desvenlafaxine succinate at 50 mg and 100 mg in outpatients with major depressive disorder in 2 placebo-controlled trials. Poster presented at: American College of Neuropsychopharmacology Annual MeetingBoca Raton, FLDecember 9–13, 2007
   Google Scholar
• Khan A, Leventhal RM, Khan SR, . Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 2002; 22:40–5
   PubMed Web of Science ®Google Scholar
• Reame NK. The emerging science of hot flash relief: legitimizing the “obecalp” effect. Menopause 2005; 12:4–7
   PubMed Web of Science ®Google Scholar
• Fava M. Prospective studies of adverse events related to antidepressant discontinuation. J Clin Psychiatry 2006; 67 (Suppl 4) 14–21
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Kennedy SH, Burrows GD, . Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19:271–80
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004; 50:57–64
   PubMed Web of Science ®Google Scholar
• Rosenbaum JF, Fava M, Hoog SL, . Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44:77–87
   PubMed Web of Science ®Google Scholar
• Sherbourne CD, Jackson CA, Meredith LS, . Prevalence of comorbid anxiety disorders in primary care outpatients. Arch Fam Med 1996; 5:27–34
   PubMedGoogle Scholar
• Effexor XR. [package insert]Collegeville, PA: Wyeth Pharmaceuticals Inc., 2006
   Google Scholar
• Cymbalta [package insert]Indianapolis, IN: Eli Lilly and Company, 2005
   Google Scholar
• Ereshefsky L, Dugan D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress Anxiety 2000; 12 (Suppl 1) 30–44
   PubMed Web of Science ®Google Scholar
• Skinner MH, Kuan HY, Pan A, . Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 2003; 73:170–7
   PubMed Web of Science ®Google Scholar
• Shams ME, Arneth B, Hiemke C, . CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006; 31:493–502
   PubMed Web of Science ®Google Scholar